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Goal:  
The goal of this activity is to increase the 
awareness of the pharmacist on the 
complications surrounding hypertension 
management in the elderly individual, 
clarify the differences in current guideline 
recommendations, and aid in making the 
most appropriate drug therapy decisions 
regarding the management of hypertension.  
Objectives 
1.  Identify the differences and similarities in 
clinical practice guideline recommendations 
for management of hypertension in the 
elderly patient.  
2.  List changes in the physiology of elderly 
individuals that create more complicated 
management scenarios 
3.  Discuss potential adverse drug effects 
that may be experienced by an elderly 
individual when prescribed anti-
hypertensive medications 
4.  Select an appropriate drug therapy 
regimen and treatment goals for an elderly 
patient with uncontrolled hypertension 
Introduction: 
Hypertension affects 70.8% of individuals 
over the age of 65, making this population 
the most likely to experience complications 
of uncontrolled hypertension such as organ 
damage and cardiovascular disease.1  
However, data to support the target blood 
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pressure goal of <140/80 mm Hg in the 
elderly population as suggested in previous 
guidelines has not been robust. Further 
complicating matters, most trials evaluating 
hypertensive goals and pharmacological 
management in recent years only included 
individuals <80 years of age.  When pooling 
results of studies including individuals 
between 80 and 90 years of age, treated 
patients showed a reduction in both stroke 
and cardiovascular morbidity, but also a 
significant increase in all-cause mortality 
compared to controls.  As a result, many 
practitioners are without clear direction 
when treating elderly patients.2, 3 Built upon 
the results of these trials that included the 
elderly population, the 2014 Evidence Based 
Guideline for the Management of High 
Blood Pressure in Adults (JNC8), along with 
the Clinical Practice Guidelines for the 
Management of Hypertension in the 
Community also released in 2014 by the 
American Society of Hypertension and 
International Society of Hypertension 
(ASH/ISH) have  resulted in a new approach 
to managing hypertension in the aging 
population. 
Pathophysiology 
Hypertension is seen with increased 
frequency in the elderly population due to 
age-associated changes in vasculature 
complicated by lifestyle changes, 
comorbidities, and use of certain 
medications (Table 1).  In the aging 
individual, large vessels become less 
distensible, endothelial dysfunction occurs, 
forward flow is reduced, and coronary 
stenosis is enhanced. Glomerulosclerosis 
and interstitial fibrosis then results in 
progressive renal dysfunction and causes 
increased intracellular sodium, reduced 
sodium-calcium exchange, and volume 
expansion which further contributes to the 
patient’s hypertension due to increased 
sodium sensitivity.2 These pathological 
changes in the elderly paired with a more 
sedentary lifestyle and medication use cause 
an elevation in systolic blood pressure (SBP) 
to become more likely. Untreated 
hypertension in the elderly is the first step in 
a cascade of events that may result in 
additional comorbidities. Poor blood 
pressure control in this population can result 
in cerebrovascular disease; coronary artery 
disease (CAD); disorders of the left 
ventricular structure and function; rhythm 
disorders; aortic and peripheral arterial 
disease; chronic kidney disease (CKD), 
ophthalmic disorders; and decreased quality 
of life.2 
Patients of African descent pose different 
challenges in the management of 
hypertension.  This population is more 
sensitive to the blood pressure raising effects 
of sodium than other groups, potentially 
explaining why these individuals tend to 
experience hypertension earlier in life and 
have more severe hypertension than other 
ethnicities.  African Americans are 
particularly vulnerable to strokes and are 3 
to 5 times more likely than Caucasians to 
have renal complications or end-stage 
kidney disease as a result of uncontrolled 
hypertension.4, 5 
Evaluating Blood Pressure Goals and 
Management 
Prior to the release of the JNC 8 and 
ASH/ISH guideline statements, the 
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American College of Cardiology Foundation 
and American Heart Association’s 
(ACCF/AHA) 2011 Expert Consensus 
Document on Hypertension in the Elderly 
was available to aid in setting blood pressure 
goals in the elderly population.  According 
to the ACCF/AHA 2011 document, the 
blood pressure goal for all individuals with 
uncomplicated hypertension was <140/90 
mm Hg. The expert panel noted that this 
recommendation was based on opinions of 
the writing panel, rather than randomized 
controlled trials, and stated for individuals 
80 years of age and older a SBP of 140 to 
145 mm Hg would be acceptable.2 
More recently, JNC 8 and ASH/ISH 
guidelines have indicated new blood 
pressure targets for the elderly population. 
As outlined in Table 2, JNC8 utilizes the 
blood pressure goal of <150/90 mmHg for 
those patients 60 years of age and older; 
while ASH/ISH imposes this same target for 
patients 80 years of age and older.4, 5 
When initiating antihypertensive 
medications in the elderly, the ACCF/AHA 
2011 Expert Panel recommends starting at 
the lowest possible dose and gradually 
increasing, depending on response, to the 
maximum tolerated dose.  A second 
medication is then added if the patient has 
not reached their blood pressure goal.2, 4, 5 
On the other hand, the strategies proposed 
by JNC8 and ASH/ISH indicate some 
patients may need multiple pharmacologic 
agents at time of diagnosis to achieve their 
goals when >20/10 mmHg above the desired 
blood pressure.4, 5 
 
Why a Difference? 
The reason for differences between the 
various guidelines lies in the evidence upon 
which each document was built.  As 
mentioned previously, the blood pressure 
goal set by the ACCF/AHA 2011 document 
was set by opinions of the expert panel.2 
ASH/ISH was similar in that the blood 
pressure goals were also set based on 
opinions of the expert writing panel, while 
JNC8 was different in that blood pressure 
goals were formulated based on reviews of 
randomized controlled trials.4,5 As dictated 
in the statement of purpose for the ASH/ISH 
guidelines, the authors were focused on 
practical applicability in the clinical setting.  
This panel further relied upon the evidence 
for a defined goal blood pressure of <140/90 
mm Hg from trials such as ACCOMPLISH, 
ALLHAT, and VALUE that included 
individuals over the age of 60 and the SBP 
goal of <150 mm Hg from the HYVET trial 
for individuals >80 years of age.5-10 On the 
other hand, JNC8 chose to utilize evidence-
based criteria using trials that evaluated 
individuals over the age of 60 such as 
SHEP, Syst-EUR, and others.11-14 Table 3 
outlines the studies that supported each 
guideline’s recommendations. 
Drug Therapy  
The majority of elderly individuals 
presenting with uncontrolled hypertension 
will have an additional comorbidity 
indicating the need for a specific 
antihypertensive medication or drug class. 
Table 4 compares recommended initial drug 
therapy options amongst the guidelines 
previously discussed. It is important to note 
initial drug therapy is based on race, not age; 
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however, when selecting appropriate therapy 
for elderly individuals the adverse effects of 
each medication (Table 5) must be 
considered as this population is more prone 
to dehydration, hypotension, and 
bradycardia due to changes in physiology.2 
While the JNC8 and ASH/ISH guidelines 
are more flexible in initial drug therapy 
choice, the ACCF/AHA 2011 expert 
consensus panel recommends a thiazide 
diuretic as the initial drug of choice.2  
Thiazide diuretics have been associated with 
reduced cardiovascular, cerebrovascular, 
and renal adverse outcomes in trials, but 
may exacerbate age-related physiological 
changes such as contracted intravascular 
volumes, orthostatic hypotension due to 
sodium and water depletion, exacerbation of 
gout, and an increased risk of arrhythmias 
due to electrolyte depletion.2,6,12,13 
Dihydropyridine (DHP) calcium channel 
blockers have been supported by positive 
evidence in controlled trials for the elderly 
population.8, 9 Since an elderly individual’s 
hypertension is characterized by arterial 
stiffness, decreased vascular compliance, 
and diastolic dysfunction, the drug’s ability 
to promote vasodilator activity make these 
drugs appealing.  It is important to note that 
similar effects are not seen with non-DHP 
calcium channel blockers such as verapamil 
and diltiazem and, when selected for 
therapy, these agents require close 
monitoring for bradycardia in this 
population. 
Other agents that may be appropriate to 
initiate in an elderly patient based on 
comorbidities require additional monitoring 
to ensure safety in this sensitive population. 
Angiotensin converting enzyme (ACE) 
inhibitors and angiotensin II receptor 
blockers (ARBs) must be accompanied by 
diligent monitoring of renal function and 
serum potassium levels but are often times 
used for their renal protective properties in 
patients with kidney disease or diabetes 
mellitus.  Beta blockers lack evidence for 
use as a primary antihypertensive agent in 
the elderly population, except in patients 
with an existing comorbidity noted in Table 
5. When these agents are selected, 
practitioners should be aware these drugs 
mask the signs of hypoglycemia in diabetic 
patients and non-selective agents may 
exacerbate pulmonary diseases.  Loop 
diuretics can be used as adjuvant therapy in 
the elderly with hypertension complicated 
by heart failure or chronic kidney disease; 
however, caution and close monitoring 
should be utilized due to these agents’ large 
adverse effect profile including increased 
glucose, electrolyte disturbances, and 
dehydration.  Finally, mineralocorticoid 
antagonists and epithelial sodium transport 
channel antagonists may be useful in 
combination with other agents for patients 
with refractory hypertension or an additional 
indication such as heart failure; however, 
close monitoring of serum potassium is 
important. 
Some antihypertensive agents, on the other 
hand, should be avoided in the elderly 
population and are listed on the Beers 
criteria and STOPP/START criteria.15, 16 
Both tools outline potentially inappropriate 
medications for older patients based on the 
medication’s potential side effects and/or the 
changing physiology of the elderly 
individual’s body.  For example, alpha 
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blockers and non-specific vasodilators, such 
as hydralazine and minoxidil, are 
recommended as last line agents due to the 
ability of these medications to increase fall 
risk secondary to the orthostatic hypotension 
these agents cause.  Additionally, alpha 
blockers should be avoided due to the 
proven excessive cardiovascular events seen 
in the ALLHAT trial.7 Alpha-agonists, such 
as clonidine, also meet Beers criteria for 
their ability to produce central nervous 
system adverse effects. 
Conclusion 
Uncontrolled hypertension is an ubiquitous 
disease state in the elderly population; 
however, given the age-related changes in 
physiology, management of these 
individuals can be complicated.  Patients 
should be evaluated on an individual basis 
for tolerability of a lower blood pressure to 
determine how restrictive their blood 
pressure goal may be, utilizing JNC8 or 
ASH/ISH guidelines in combination with 
the ACCF/AHA 2011 expert consensus 
guidelines.  Practitioners must also take 
comorbidities, drug burden, and potential for 
adverse effects into consideration when 
choosing an antihypertensive therapy 
appropriate for their elderly patient. 
 
 The Pharmacists Education 
Foundation (PEF) is accredited by 
the Accreditation Council for Pharmacy 
Education (ACPE) as a provider of 
continuing pharmacy education.  To receive 
continuing pharmacy education (CPE) 
pharmacists MUST COMPELTE THE 
ONLINE QUIZ AND EVALUATION 
FORM. A score of 70% or above is required 
to receive CPE credit.  The link to the quiz 
can be accessed from the home study section 
in the CE Portal of the IPA website, 
www.indianapharmacists.org.  This is a free 
service of IPA members in 2015.  Initial 
release date: 10/30/2015. Expiration Date: 
10/30/2018. Questions: Call IPA office at 
317-634-4968. 
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TABLE 1 
Factors That Worsen Hypertension in the Elderly2 
Lifestyle Changes Comorbidities Medications 
 Smoking and alcohol use 
 
 Limited physical activity 
 
 Altered or reduced 
appetite 
 
 Excessive sodium intake 
 Renal artery stenosis 
 
 
 Obstructive sleep apnea 
 
 Primary aldosteronism 
 
 Thyroid disorders 
 Nonsteroidal anti-inflammatory 
drugs (NSAIDs) 
 
 Glucocorticoids 
 
 Sex hormones 
 
 Antirheumatic agents (e.g. 
cyclosporine, leflunomide) 
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TABLE 2 
Blood Pressure Goals 2, 4, 5 
 Uncomplicated Hypertension DM CKD 
ACCF/AHA 
2011 
All patients: <140/90 mm Hg 
>80 years of age: 140 to 145 mm Hg 
systolic can be acceptable 
<130/80 mm Hg <130/80 mm Hg 
JNC8 < 60 years of age: <140/90 mm Hg 
> 60 years of age: <150/90 mm Hg  
<140/90 mm Hg <140/90 mm Hg 
ASH/ISH <80 years of age: <140/90 mm Hg 
>80 years of age: <150/90 mm Hg  
<140/90 mm Hg <140/90 mm Hg 
CKD: chronic kidney disease, DM: diabetes mellitus 
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TABLE 3 
 
Hypertension Trials 
 
Trial 
Study 
Participants 
Pharmacologic 
Intervention 
Important Considerations and 
Results 
ACCOMPLISH8 N= 11,506 
Mean Age: 
68 
(Benazepril + 
amlodipine) vs. 
(benazepril + 
HCTZ) 
 Goal BP: <140/90 mm Hg, 
<130/80 mmHg in participants 
with history of DM 
 ACEI/ CCB combination is 
superior to ACEI/ HCTZ in 
reduction in morbidity and 
mortality 
 40% of participants were 70 
years of age or older 
 No difference in morbidity 
and mortality in those >80 
years of age 
ALLHAT7 N=33,357 
Mean Age: 
67 
Amlodipine, 
lisinopril or 
doxazozin vs. 
chlorthalidone 
 Goal BP: <140/90 mmHg 
 25% increase in CV events in 
doxazosin arm including a 
204% increase in HF and 19% 
increase in stroke 
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 57% of participants were 65 
years of age or older 
HYVET6 N=3,845 
Mean Age: 
84 
Indapamide +/- 
perindopril 
 Goal BP: <150/80 mmHg 
 All patients were 80 years of 
age or older 
 Reduction of stroke, HF, and 
CV events in the indapamide 
arm 
 Significant reduction in all-
cause death 
INVEST10 
 
 
N=22,576 
Mean Age: 
66 
Verapamil vs. 
atenolol 
 Goal BP: <140/90 mmHg, 
<130/85 mmHg in participants 
with history of DM 
 33% of participants were 70 
years of age or older 
 No difference in outcomes in 
those >80 years of age 
SHEP13 N=4,736 
Mean Age: 
72 
Chlorthalidone  Goal SBP: <150 mmHg 
 Reduced incidence of stroke in 
all patients in treatment arm 
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Syst-EUR14 N=4,695 
Mean Age: 
70 
Nitrendipine  Goal SBP: <150 mmHg 
 Treatment to goal BP 
improves CV and 
cerebrovascular outcomes and 
lowers mortality 
ACE: angiotensin converting enzyme; BP: blood pressure; CCB: calcium channel blocker; CV: 
cardiovascular; HCTZ: hydrochlorothiazide; HF: heart failure; SBP: systolic blood pressure 
TABLE 4 
Initial Treatment Options for Uncomplicated Hypertension 2, 4, 5 
 Non-African American Individuals African American 
Individuals 
ACCF/AHA 2011  Thiazide-type diuretic  Thiazide-type diuretic 
JNC8 ACE inhibitor 
ARB 
CCB 
Thiazide-type diuretic 
CCB 
Thiazide-type diuretic 
ASH/ISH <60 years of age 
ACE inhibitor 
ARB 
 
>60 years of age 
CCB 
Thiazide-type 
diuretic 
CCB 
Thiazide-type diuretic 
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CCB: calcium 
channel blocker 
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TABLE 5 
Drug Therapy Options for the Elderly 2, 5 
 
 
Drug Class Important Considerations Monitoring 
Thiazide diuretics 
 
 Promotes orthostatic hypotension, 
depletion of electrolytes, 
hyperuricemia, glucose intolerance 
and dyslipidemia  
 Sodium, potassium, 
magnesium 
 Volume status 
 Blood glucose 
 Fasting lipid panel 
 Uric acid level 
 CrCl: not effective in 
patients with CrCl 
<30 ml/min 
Calcium channel 
blockers 
 
 Associated with postural 
hypotension with an increased risk 
of dizziness and falls  
 Verapamil and diltiazem may 
precipitate heart block in those with 
underlying defects  
 Bradycardia (most 
common with DHP 
CCB) 
 Ankle edema 
 Headache 
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 Avoid verapamil, diltiazem, and 
nifedipine in those with preserved 
ejection fraction heart failure 
 Constipation (most 
common with 
verapamil) 
ACE inhibitors  May cause chronic dry cough, 
angioedema, hyperkalemia, and 
renal failure  
 More effective in reducing BP in 
white patients than African 
Americans 
 Angioedema (more 
common in African 
American patients) 
 Potassium 
 Renal function; may 
increase SCr up to 
30% 
 May need to start at 
lower initial dose for 
CrCl<30 ml/min 
ARBs  May cause chronic dry cough, 
angioedema, hyperkalemia, and 
renal failure  
 More effective in reducing BP in 
white patients than African 
Americans 
 
 Angioedema (less 
common than ACE 
inhibitors) 
 Potassium 
 Renal function; may 
increase SCr up to 
30% 
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Direct renin 
inhibitors 
 May cause hypotension, 
hyperkalemia, and renal failure  
 Potassium 
 Renal function 
Beta blockers 
 
Alpha-beta 
blockers 
 Useful in elderly patients who have 
CAD, HF, certain arrhythmias, 
migraine headaches, or tremor  
 May mask signs of hypoglycemia 
in patients with DM 
 Bradycardia 
 Depression 
 Sexual dysfunction 
 Fasting lipid panel 
Loop diuretics  Useful in patients with volume 
overload (ie. HF and CKD) 
 May cause electrolyte disturbances 
and glucose intolerance  
 Potassium, 
magnesium 
 Volume status 
 Fasting lipid panel 
 Blood glucose 
 Uric acid level 
Mineralocorticoid 
antagonists 
 Does not cause metabolic 
disturbances 
 May cause hyperkalemia; avoid in 
combination with ACE inhibitors 
and ARBs 
 Gynecomastia and 
sexual dysfunction in 
men treated with 
spironolactone 
 Potassium 
 Dose adjusted with 
CrCl <50 ml/min, not 
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recommended <30 
ml/min 
Epithelial sodium 
transport channel 
antagonists  
(amiloride and 
triamterene) 
 Does not cause metabolic 
disturbances 
 Minimal effect on BP; used mostly 
for potassium sparing effect in 
combination with diuretics 
 Potassium 
 Use not 
recommended with 
CrCl <50 ml/min 
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, BP: blood pressure, 
CAD: coronary artery disease, CCB: calcium channel blockers; CKD: chronic kidney disease , 
CrCl: creatinine clearance,  DHP: dihydropyridine, DM: diabetes mellitus, HF: heart failure, 
SCr: serum creatinine 
 
